Skip to main content

Advertisement

Table 1 EGFR-TKIs versus chemotherapy as second-line treatment for advanced NSCLC patients harboring wild-type EGFR mutations

From: Targeted therapies for patients with advanced NSCLC harboring wild-type EGFR: what’s new and what’s enough

Trial Detection technique Treatment PFS (months) HR for PFS (95% CI) OS (months) HR for OS (95% CI) Reference
TAILOR Sequencing Erlotinib 2.4 0.71 (0.53–0.95) 5.4 0.73 (0.53–1.00) [18]
Docetaxel 2.9 8.2
DELTA PCR-based methods Erlotinib 1.3 1.45 (1.09–1.94) 9.0 0.98 (0.69–1.39) [19]
Docetaxel 2.9 10.1
CTONG0806 DNA sequencing Gefitinib 1.7 0.53 (0.38–0.75) 9.6 0.72 (0.49–1.04) [20]
ARMS Pemetrexed 5.6 12.4
  1. EGFR epidermal growth factor receptor, TKIs tyrosine kinase inhibitors, NSCLC non-small cell lung cancer, PCR polymerase chain reaction, ARMS Scorpion amplification refractory mutation system, PFS progression-free survival, HR hazard ratio, CI confidence interval, OS overall survival.